Morinaga & Co Ltd operates in the Candy & other confectionery products sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Morinaga & Co Ltd with three other
bakery and confectionary companies in Asia:
GlaxoSmithKline Consumer Healthcare Limited
sales of 39.86 billion Indian Rupees [US$619.10 million]
of which 100%
Imuraya Group Company Limited
(42.00 billion Japanese Yen [US$370.00 million]
of which 88%
was Distribution Business), and
Nakamuraya Co., Ltd.
(41.90 billion Japanese Yen [US$369.15 million]
of which 71%
was Confectionery Business).
Morinaga & Co Ltd reported sales of ¥199.48 billion (US$1.76 billion)
March of 2017.
increase of 9.7%
versus 2016, when the company's sales were ¥181.87 billion.
Sales at Morinaga & Co Ltd have increased during each of the previous five years
(and since 2012, sales have increased a total of 36%).
Sales of Wholesale Food and Restaurant saw an increase
10.4% in 2017, from
¥6.21 billion to ¥6.86 billion.
Not all segments of Morinaga & Co Ltd experienced an increase in sales in 2017:
sales of Other fell 17.0% to ¥552.00 million.
(However, this segment's sales were only a very small portion of the company's overall sales).
Morinaga & Co Ltd also experienced decreases in sales in
Real Estate and Services (down 3.9% to ¥2.46 billion)